Jellyana Peraza, MD
Assistant ProfessorCards
About
Research
Publications
2026
Sa1613 BODY FAT COMPOSITION AND MAJOR OUTCOMES IN PATIENTS WITH PERIANAL FISTULIZING CROHN’S DISEASE
Bergenholtz S, Cho W, Peraza J, Freid H, Lahoti Y, Blankemeier L, Fettahoglu A, Chaudhari A, Boutin R, Gold S, Wong S. Sa1613 BODY FAT COMPOSITION AND MAJOR OUTCOMES IN PATIENTS WITH PERIANAL FISTULIZING CROHN’S DISEASE. Gastrointestinal Endoscopy 2026, 103: s-1009. DOI: 10.1016/s0016-5107(26)02554-x.Peer-Reviewed Original ResearchSa1613 BODY FAT COMPOSITION AND MAJOR OUTCOMES IN PATIENTS WITH PERIANAL FISTULIZING CROHN’S DISEASE
Bergenholtz S, Cho W, Peraza J, Freid H, Lahoti Y, Blankemeier L, Fettahoglu A, Chaudhari A, Boutin R, Gold S, Wong S. Sa1613 BODY FAT COMPOSITION AND MAJOR OUTCOMES IN PATIENTS WITH PERIANAL FISTULIZING CROHN’S DISEASE. Gastroenterology 2026, 170: s-1009. DOI: 10.1016/s0016-5085(26)02623-5.Peer-Reviewed Original ResearchAutomating clinical phenotyping using natural language processing
Schmidt L, Ibing S, Borchert F, Hugo J, Marshall A, Peraza J, Cho J, Böttinger E, Renard B, Ungaro R. Automating clinical phenotyping using natural language processing. Communications Medicine 2026, 6: 77. PMID: 41530528, PMCID: PMC12873203, DOI: 10.1038/s43856-025-01337-0.Peer-Reviewed Original ResearchElectronic health recordsF1 scorePerformance of human expertsNatural language processingInter-annotator agreementHealth recordsRule-based approachClinical narrative textComputable phenotypeGround-truth dataLanguage modelHuman expertsClinical textChart review processSentence-levelLanguage processingManual chart reviewPatient's clinical phenotypeComplex taskDisease behaviorPhenotyping algorithmsTruth dataPatient levelClinical phenotypeNote-level
2025
Statin Use is Associated With Lower Odds of IBD-Related Surgery Among Patients With Moderate-to-Severe Inflammatory Bowel Disease
Claytor J, Rajauria P, Peraza J, Colombel J, Ungaro R. Statin Use is Associated With Lower Odds of IBD-Related Surgery Among Patients With Moderate-to-Severe Inflammatory Bowel Disease. Inflammatory Bowel Diseases 2025, 32: 253-260. PMID: 41418331, PMCID: PMC12857421, DOI: 10.1093/ibd/izaf227.Peer-Reviewed Original ResearchIBD-related surgeryInflammatory bowel diseaseStatin usersRetrospective cohort studyIBD hospitalizationsIBD surgeryFollow-upTherapy persistenceRetrospective cohort study of patientsOdds ratioBowel diseaseLow riskCohort study of patientsMount Sinai Data WarehouseCox regression analysisImpact of statinsStudy of patientsModerate-to-severeOutpatient follow-upIBD-related hospitalizationMultivariate regression analysisInternational ClassificationHazards of surgeryRegression analysisPropensity score matchingMild Crohn’s Disease Is Associated With Altered Sphingolipid Metabolism and Reduced Neutrophilic Inflammation
Bourgonje A, Ibing S, Rajauria P, Peraza J, Consortium T, Ananthakrishnan A, Argmann C, Dubinsky M, Jacobsen H, Jess T, Larsen L, Renard B, Sands B, Shah S, Shapiro J, Suarez-Fariñas M, Colombel J, Ungaro R. Mild Crohn’s Disease Is Associated With Altered Sphingolipid Metabolism and Reduced Neutrophilic Inflammation. Gastroenterology 2025, 169: 1294-1297. PMID: 40701397, DOI: 10.1053/j.gastro.2025.06.026.Peer-Reviewed Original ResearchA Simple Endoscopic Score for Crohn's Disease (SES‐CD) ≥ 7 Predicts Disease Progression
Peraza J, Kaper M, Bargas A, Kim I, Agrawal M, Larsen L, Jacobsen H, Jess T, Colombel J, Torres J, Ungaro R, Ananthakrishnan A. A Simple Endoscopic Score for Crohn's Disease (SES‐CD) ≥ 7 Predicts Disease Progression. Alimentary Pharmacology & Therapeutics 2025, 61: 1011-1018. PMID: 39757503, PMCID: PMC11870798, DOI: 10.1111/apt.18492.Peer-Reviewed Original ResearchConceptsAssociated with lower likelihoodSES-CDDisease progressionCrohn's diseaseMild CDEndoscopic scorePrimary outcomeMulticentre retrospective cohort studyMultivariate Cox proportional hazards modelRisk of progressionTertiary care centreMild disease coursePrediction of disease progressionRetrospective cohort studyCox proportional hazards modelsLong-term disease progressionProportional hazards modelImmunosuppressive therapyEndoscopic severityPenetrating diseaseEndoscopic assessmentDisease courseCohort studyCare centrePatients
2024
Disparities in Gender and Race Representation Among Authors of Inflammatory Bowel Disease Clinical Trials
Gros B, Peraza J, Bassi M, Sleiman J, Abdelhalim S, Park E, Wong S, Agrawal M, Grinspan L, Charabaty A. Disparities in Gender and Race Representation Among Authors of Inflammatory Bowel Disease Clinical Trials. Journal Of Crohn's And Colitis 2024, 19: jjae184. PMID: 39657593, PMCID: PMC13031988, DOI: 10.1093/ecco-jcc/jjae184.Peer-Reviewed Original ResearchConceptsInflammatory bowel diseaseInflammatory bowel disease clinical trialsClinical trialsPrincipal investigatorNonwhite individualsIndustry-sponsored trialsSenior authorPublished Clinical TrialsFemale physiciansRacial disparitiesSingle-centerTherapy trialsSystem interventionsMinority populationsResearch authorshipBowel diseaseTrial characteristicsAssociated FactorsManagement of Overweight and Obesity in Patients With Inflammatory Bowel Disease.
Shneyderman M, Freid H, Kohler D, Peraza J, Haskey N, Abbott E, Kornbluth A, Raman M, Gold S. Management of Overweight and Obesity in Patients With Inflammatory Bowel Disease. Gastroenterology & Hepatology 2024, 20: 712-722. PMID: 39886003, PMCID: PMC11776002.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsInflammatory bowel diseaseWeight management strategiesInflammatory bowel disease guidelinesBowel diseaseComplication of inflammatory bowel diseaseGlucagon-like peptide-1 agonistsAnti-obesity medicationsInflammatory bowel disease providersIBD coursePeptide-1 agonistsBariatric surgeryDisease courseLifestyle modificationObesity managementWeight managementObesityPatientsIntervention studiesIncreasing evidenceDiseaseEfficacyTreatmentSurgeryComplicationsManagement strategiesThe Rising Epidemic of Obesity in Patients with Inflammatory Bowel Disease
Peraza J, Abbott E, Shneyderman M, Kornbluth A, Raman M, Gold S. The Rising Epidemic of Obesity in Patients with Inflammatory Bowel Disease. Current Treatment Options In Gastroenterology 2024, 22: 134-144. DOI: 10.1007/s11938-024-00453-5.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsInflammatory bowel disease patientsResponse to therapyInflammatory bowel diseasePrevalence of obesityBody mass indexObesity ratesVisceral adiposityGrowing prevalenceInflammatory bowel disease incidenceBowel diseaseInflammatory bowel disease outcomesEpidemic of obesityVisceral fat measurementHigh-risk populationSurgical outcomesClinical outcomesMass indexTreatment strategiesPatientsObesityDisease pathophysiologyDisease severityTherapyEpidemiological dataFat measurementsRisk of Adverse Cardiovascular Outcomes in Postmenopausal Women with Inflammatory Bowel Disease
Greywoode R, Larson J, Peraza J, Clark R, Allison M, Chaudhry N, Schnatz P, Shadyab A, Wallace R, Wassertheil-Smoller S. Risk of Adverse Cardiovascular Outcomes in Postmenopausal Women with Inflammatory Bowel Disease. Digestive Diseases And Sciences 2024, 69: 2586-2594. PMID: 38684633, PMCID: PMC11258184, DOI: 10.1007/s10620-024-08348-2.Peer-Reviewed Original ResearchConceptsWomen's Health InitiativeRisk of ischemic strokeCoronary heart diseasePeripheral arterial diseaseExcess riskCardiovascular diseaseExcess risk of ischemic strokeWomen's Health Initiative participantsConclusionsAmong postmenopausal womenRisk of coronary heart diseaseInflammatory bowel disease diagnosisIschemic strokeInflammatory bowel diseaseCardiovascular disease outcomesAdverse CVD outcomesWomen's Health Initiative trialCardiovascular disease riskTraditional cardiovascular diseaseIBD womenCox proportional hazards modelsVenous thromboembolismRisk of outcomesHealth initiativesProportional hazards modelLifestyle factors
Academic Achievements & Community Involvement
Teaching & Mentoring
Clinical Care
Overview
Jellyana Peraza, MD, is a gastroenterologist who specializes in the treatment of digestive disorders, particularly inflammatory bowel disease (IBD). She focuses on identifying and managing conditions such as Crohn’s disease and ulcerative colitis, helping patients alleviate symptoms and enhance quality of life.
As an assistant professor at Yale School of Medicine, Dr. Peraza is involved in research aimed at improving the understanding and treatment of gastrointestinal diseases.
Dr. Peraza received her medical training from the Universidad Central de Venezuela. She completed her residency and served as chief resident in internal medicine at Montefiore Medical Center, and pursued her fellowship in gastroenterology at the Icahn School of Medicine at Mount Sinai.
Clinical Specialties
Gastroenterology; Inflammatory Bowel Disease
News
Get In Touch
Contacts
Appointment Number
Clinic Fax Number
Mailing Address
Yale School of Medicine
Department of Medicine (Digestive Diseases), P.O. Box 208019
New Haven, Connecticut 06520-8019
United States
Administrative Support
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.